LLY Jan 2026 670.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:54AM EDT. Market open.
Loading interactive chart…
- PR Newswire
Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution
Eli Lilly and Company (NYSE: LLY) announced detailed results from the SURMOUNT-OSA phase 3 clinical trials evaluating tirzepatide injection (10 mg or 15 mg) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, with and without positive airway pressure (PAP) therapy. In both studies, tirzepatide achieved all primary and key secondary endpoints for both the efficacyi and treatment-regimenii estimands and demonstrated a mean reduction of up to 62.8% on the a
- Barrons.com
Eli Lilly’s Weight-Loss Franchise Has Been a Massive Winner Under Dave Ricks
Zepbound and related products could generate more than $50 billion of sales in 2029. There is a lot more in Lilly’s pipeline.
- Zacks
Here's How Much a $1000 Investment in Eli Lilly Made 10 Years Ago Would Be Worth Today
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
© 2024 Yahoo. All rights reserved.